We offer an opportunity to invest in carefully selected life science companies
Our employees have extensive experience of research, development, financing and commercialization of pharmaceutical and medtech projects. This expertise enables us to select attractive investment objects, to monitor the development of our portfolio companies, and to ensure that they have the right team composition and structure – both in order to progress the projects and to ensure value-generating licensing deals, divestments, or IPOs, based on their successes.
Key components to understand the value of KDventures
KDventures has historically invested in syndicates together with leading life science investors, industrial partners and specialist funds across Sweden, Europe and the U.S. This model allows KDventures to share development and financing risk, while giving portfolio companies access to broader capital, sector expertise and long-standing international networks.
The syndicated model also provides external validation of KDventures’ investment decisions. Historically and in its current portfolio, KDventures has invested alongside experienced investors such as Industrifonden, HealthCap, Linc, Novo Holdings, Novartis, Organon, Merck, Rosetta Capital and others. These collaborations have given KDventures access to shared due diligence, active co-investment and broader sector expertise, while enabling portfolio companies to be supported through multiple development stages.
Across KDventures-backed companies, specialised investors have historically invested approximately seven times more capital than KDventures’ own invested capital. This illustrates the leverage of KDventures’ investment model: the company can build exposure to high-potential life science assets while mobilising substantially larger amounts of external capital around its portfolio companies.
Historically, part of this syndicated investment model was structured through KDev Investments AB, including holdings in Aprea, Modus, Dilafor and Promimic. Following the acquisition of Rosetta Capital’s shares in KDev Investments AB, KDventures removes the previous waterfall structure and obtains a cleaner, more transparent and more direct exposure to the future value development of these portfolio holdings.
A valuation of KDventures’s holdings is carried out every quarter, based on international accounting principles (IFRS 13 and IPEV). The Portfolio Fair Value is divided into:
Total Portfolio Fair Value, which is the aggregate return that would be obtained by KDventures and KDev Investments if the shares in the portfolio companies were to be divested in an orderly transaction between market operators.
Net Portfolio Fair Value, which is the net aggregate dividend that KDventures will receive after KDev Investments’ dividend payment to Rosetta Capital.
KDventures’s share (KDEV) is listed on the NASDAQ Stockholm Stock Exchange.
KDventures has historically invested in syndicates together with leading life science investors, industrial partners and specialist funds across Sweden, Europe and the U.S. This model allows KDventures to share development and financing risk, while giving portfolio companies access to broader capital, sector expertise and long-standing international networks.
The syndicated model also provides external validation of KDventures’ investment decisions. Historically and in its current portfolio, KDventures has invested alongside experienced investors such as Industrifonden, HealthCap, Linc, Novo Holdings, Novartis, Organon, Merck, Rosetta Capital and others. These collaborations have given KDventures access to shared due diligence, active co-investment and broader sector expertise, while enabling portfolio companies to be supported through multiple development stages.
Across KDventures-backed companies, specialised investors have historically invested approximately seven times more capital than KDventures’ own invested capital. This illustrates the leverage of KDventures’ investment model: the company can build exposure to high-potential life science assets while mobilising substantially larger amounts of external capital around its portfolio companies.
Historically, part of this syndicated investment model was structured through KDev Investments AB, including holdings in Aprea, Modus, Dilafor and Promimic. Following the acquisition of Rosetta Capital’s shares in KDev Investments AB, KDventures removes the previous waterfall structure and obtains a cleaner, more transparent and more direct exposure to the future value development of these portfolio holdings.
A valuation of KDventures’s holdings is carried out every quarter, based on international accounting principles (IFRS 13 and IPEV). The Portfolio Fair Value is divided into:
Total Portfolio Fair Value, which is the aggregate return that would be obtained by KDventures and KDev Investments if the shares in the portfolio companies were to be divested in an orderly transaction between market operators.
Net Portfolio Fair Value, which is the net aggregate dividend that KDventures will receive after KDev Investments’ dividend payment to Rosetta Capital.
KDventures’s share (KDEV) is listed on the NASDAQ Stockholm Stock Exchange.
